Single drugs versus a combination pill in hypertension and type 2 diabetes
Compares single drugs with HL1113 in hypertension and type 2 diabetes.
Key facts
- Who runs it
- Hanlim Pharm. Co., Ltd.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 228 people, planned
- Started
- 18 Dec 2025
- Expected to end
- Dec 2028
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Test group
- Exploratory test group
- Control group 1
- Control group 2
- Record updated
- 27 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have both essential hypertension (high blood pressure) and type 2 diabetes. It compares single-drug treatment with a fixed-dose combination.
- Age
- 19 years or older
- Sex
- Women and men can join.
- Disease stage
- Essential hypertension together with type 2 diabetes mellitus.
Main reasons for not taking part
- Diastolic blood pressure (MSDBP) of 110 mmHg or more in the selected arm at both screening and randomization
- A difference of 20 mmHg or more in systolic blood pressure, or 10 mmHg or more in diastolic blood pressure, between the two arms at screening
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult male or female subjects aged ≥19 years at the time of written informed consent
- Subjects diagnosed with essential hypertension accompanied by type 2 diabetes mellitus
- etc
Who cannot take part
- Subjects whose blood pressure measured in the selected arm at both screening and randomization meets the following criterion: MSDBP ≥ 110 mmHg
- Subjects whose blood pressure measured three consecutive times in each arm at intervals of at least 2 minutes at screening shows a difference of ≥20 mmHg in SBP and ≥10 mmHg in DBP
- etc
Where in South Korea
- The Catholic University of Korea Bucheon St.Mary's HospitalSeoul, South KoreaContact: LimTaking people
About the trial
What the trial wants to find out
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus
The 4 groups in the trial
- Test groupTreatment being tested
- Exploratory test groupTreatment being tested
- Control group 1Placebo, for comparison
- Control group 2Placebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Active Controlled, Double Blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
- Plain-language title
- Single drugs versus a combination pill in hypertension and type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 27 April 2026